Glaucoma
Conditions
Brief summary
This clinical trial is designed to investigate the performance of SENSIMED Triggerfish® during 24-hour continuous IOP fluctuation monitoring, defined as the number of valid recording intervals over the 24-hour period. The investigation will recruit male and female patients older than 18 years and diagnosed with glaucoma and treated with tafluprost in both eyes. 20 subjects will be enrolled in the study. Patients will be considered enrolled in the study upon signature of informed consent. A screening visit and one 24-hour IOP fluctuation monitoring session during a 36-hour hospitalisation, are planned for each patient.
Interventions
DEVICESENSIMED Triggerfish
Contact lens-based device for the continuous recording of IOP fluctuations, with a portable recording system
Sponsors
University Hospital, Geneva
Sensimed AG
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Older than 18 years. * Untreated IOP of ≥22 mmHg in both eyes. * Documented, typical glaucomatous visual field (VF) loss (nasal step, or arcuate, paracentral or Seidel's scotoma) determined by automated static threshold perimetry (Octopus 100), and glaucomatous optic nerve head cupping (neural rim notching or saucerization) in both eyes. * Patients under tafluprost treatment since at least 4 weeks in both eyes. * Patients who accept signing an informed consent approved by the Ethics Committee.
Exclusion criteria
* Patients not able to understand the nature of the research * Patients under tutorship * Corneal abnormalities in both eyes * Subjects with contraindications for wearing contact lenses * History of ocular surgery within the last 3 months * Known hypersensitivity to tafluprost or to any of its excipients * Full-frame metal glasses during monitoring with SENSIMED Triggerfish® * Pregnancy and lactation * Simultaneous participation in other clinical research * Patients with evidence of ocular infection or inflammation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Acquisition of 24-hour Sensor output signal | After 24-hour continuous recording | Performance is assessed as the portion of valid data (actual number of valid data points recorded compared to expected number of recorded data points) during 24-hour recording. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Possible IOP fluctuation | After 24-hour recording with study device | Fluctuation is defined as a change of 25% or more from the mean Sensor output over 24 hours for each participant. |
Countries
Switzerland
Outcome results
None listed